New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Alimera Sciences, Inc.
ALIM
Shape
US Flag

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

301M

Drug Manufacturers - Specialty & Generic

Next Earning date - 24 Oct 2024

301M

Drug Manufacturers - Specialty & Generic

Next Earning date - 24 Oct 2024

5.54USD
0.00 ( 0.00%)
favorite-chart

Relative Strenght

39
favorite-chart

Volume Buzz

248%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

2%

Quote Panel

Shape
Updated October 12, 2024
1W % 1M 0.00 % 3M -0.36 % 1Y 110.65 %

Key Metrics

Shape
  • Market Cap

    301.29M


  • Shares Outstanding

    54.38M


  • Share in Float

    13.18M


  • Dividende

    0


  • Earning Date

    24 Oct 2024


  • Price Target

    5.54


  • Average Volume

    866825


  • Beta

    1.245


  • Range

    2.606-5.65


  • Industry

    Drug Manufacturers - Specialty & Generic


  • Website

    https://alimerasciences.com


  • Sector

    Healthcare


Fundamentals

Shape

N/A

P/E Ratio

3.02x

P/S Ratio

7.77x

P/B Ratio

1.8

Debt/Equity

-14.7%

Net Margin

$1.1

EPS

How ALIM compares to sector?

P/E Ratio

Relative Strength

Shape

ALIM

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$121M

Shape348%

2025-Revenue

$0.19

Shape412%

2025-EPS

$985K

Shape-132%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Alliance Global Partners

downgrade

Previous: Buy

2024-06-25

Now: Neutral

H.C. Wainwright

downgrade

Previous: Not converted

2024-06-25

Now: Neutral

Craig-Hallum

downgrade

Previous: Not converted

2024-06-24

Now: Hold

Raymond James

upgrade

Previous: Not converted

2023-06-12

Now: Strong Buy

Earnings GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

N/A

-0.75
vs -0.60

Q4.22

arrow
arrow

N/A

-0.54
vs -0.59

Q1.23

arrow
arrow

N/A

-0.71
vs -0.85

Q2.23

arrow
arrow

N/A

-0.44
vs -0.45

Q3.23

arrow
arrow

N/A

-0.06
vs -0.75

Q4.23

arrow
arrow

N/A

-0.07
vs -0.54

Q1.24

arrow
arrow

N/A

-0.12
vs -0.71

Q2.24

arrow
arrow

N/A

-0.06
vs -0.44

Q3.24

arrow
arrow

N/A

-0.01
vs -0.06

Q4.24

arrow
arrow

+152%

0.04
vs -0.07

Sales GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

+12%

13.6M  vs 12.2M

Q4.22

arrow
arrow

+1%

14M  vs 14M

Q1.23

arrow
arrow

+14%

13.5M  vs 11.9M

Q2.23

arrow
arrow

+20%

17.5M  vs 14.6M

Q3.23

arrow
arrow

+72%

23.4M  vs 13.6M

Q4.23

arrow
arrow

+88%

26.3M  vs 14M

Q1.24

arrow
arrow

+70%

23M  vs 13.5M

Q2.24

arrow
arrow

+54%

27M  vs 17.5M

Q3.24

arrow
arrow

+17%

27.4M  vs 23.4M

Q4.24

arrow
arrow

+14%

29.9M  vs 26.3M

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

+29%

0.29
vs 0.25

Q4.22

arrow
arrow

+18%

0.18
vs 0.29

Q1.23

arrow
arrow

+44%

0.44
vs 0.18

Q2.23

arrow
arrow

-22%

-0.22
vs 0.44

Q3.23

arrow
arrow

-3%

-0.03
vs -0.22

Q4.23

arrow
arrow

-8%

-0.08
vs -0.03

Q1.24

arrow
arrow

-15%

-0.15
vs -0.08

Q2.24

arrow
arrow

-9%

-0.09
vs -0.15

Institutionnal OwnershipShape

status-upQoQ

Q3.22

arrow
arrow

12

12
vs 17

-29%

Q4.22

arrow
arrow

20

20
vs 12

67%

Q1.23

arrow
arrow

16

16
vs 20

-20%

Q2.23

arrow
arrow

17

17
vs 16

6%

Q3.23

arrow
arrow

28

28
vs 17

65%

Q4.23

arrow
arrow

34

34
vs 28

21%

Q1.24

arrow
arrow

38

38
vs 34

12%

Q2.24

arrow
arrow

53

53
vs 38

39%

Earnings Growth

Latest News